Insights Into Renal Cell Carcinoma (RCC)
Perspectives on drivers in treatment decisions in the management of RCC
Southeast #1 – March 10, 2023
Faculty Chair
Tian Zhang, MD
Duke Cancer Center, Durham, NC, USA
Central – May 2, 2023
Faculty Chair
Eric Jonasch, MD
MD Anderson Cancer Center, Houston, TX, USA
Southeast #2 – May 17, 2023
Faculty Chair
Mehmet Bilen, MD
Winship Cancer Institute, Atlanta, GA, USA
West – July 17, 2023
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center, Duarte, CA, USA
Northeast – August 9, 2023
Faculty Chair
Bradley McGregor, MD
Dana Farber Cancer Institute, Boston, MA, USA
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- West
More Information
- Baltimore, MD
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
